Derek Klemm
Addiction Medicine · Demorest, GANPI 1225300494
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 299 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,258, 6.6 times the $190 reported in 2019. Among addiction medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 299 payments — averaging $17.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Corcept Therapeutics$371
- GSK$324
- Lilly USA, LLC$301
- Gilead$295
- Alkermes, Inc.$281
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,05798%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 85 | $1,010 |
| Corcept Therapeutics | 18 | $371 |
| GSK | 18 | $324 |
| Lilly USA, LLC | 21 | $301 |
| Gilead | 14 | $295 |
| Alkermes, Inc. | 12 | $281 |
| Boehringer Ingelheim | 13 | $264 |
| AstraZeneca | 15 | $256 |
| Exact Sciences | 10 | $207 |
| Braeburn Inc. | 8 | $185 |
| Daiichi Sankyo Inc. | 10 | $180 |
| Xeris Pharmaceuticals, Inc. | 8 | $168 |
| Vanda Pharmaceuticals Inc. | 9 | $165 |
| Bayer | 6 | $122 |
| Astellas Pharma US Inc | 3 | $122 |
| Pfizer | 7 | $115 |
| Otsuka America Pharmaceutical, Inc. | 5 | $111 |
| Novo Nordisk | 6 | $106 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $43 |
| Abbott | 2 | $42 |
| Sanofi Pasteur Inc. | 3 | $41 |
| Genentech USA, Inc. | 2 | $39 |
| Mylan Specialty L.p. | 2 | $38 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $37 |
| Indivior Inc. | 2 | $35 |
| Vertex | 1 | $35 |
| Amgen | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Masimo Corporation | 1 | $21 |
| Medtronic | 1 | $20 |
| Lundbeck LLC | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
How this compares
$5,157 in reported general payments places this provider in the 90th percentile of 35 addiction medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 144 | $115,181 |
| EliquisApixaban | 103 | $93,507 |
| OzempicSemaglutide | 73 | $67,442 |
| TrulicityDulaglutide | 46 | $58,035 |
| MounjaroTirzepatide | 40 | $57,811 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 70 | $56,101 |
| RybelsusSemaglutide | 29 | $46,794 |
| XareltoRivaroxaban | 43 | $45,110 |
| TradjentaLinagliptin | 33 | $41,420 |
| JardianceEmpagliflozin | 28 | $38,403 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $38,314 |
| LinzessLinaclotide | 34 | $32,861 |
| FarxigaDapagliflozin Propanediol | 42 | $31,165 |
| MyrbetriqMirabegron | 38 | $27,397 |
| RexultiBrexpiprazole | 19 | $26,948 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $301 | $115,84686 claims |
| Novo NordiskOzempic, Rybelsus | $106 | $114,236102 claims |
| PfizerEliquis | $115 | $93,507103 claims |
| Boehringer IngelheimTradjenta, Jardiance | $264 | $79,82361 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $324 | $76,927103 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $256 | $66,203104 claims |
| AbbVieLinzess, Vraylar | $1,010 | $58,02352 claims |
| Johnson & JohnsonXarelto | $14 | $45,11043 claims |
| Astellas Pharma US IncMyrbetriq | $122 | $27,39738 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $111 | $26,94819 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $3,028340 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 35 addiction medicine providers in Georgia.
Other addiction medicine in Demorest
- Kimberlynn RichardsSmyrna$14K
- Tommie RichardsonSmyrna$14K
- Daniel GolightlySmyrna$2K
- Scott MilesSt.mary's$887
- Roy AryAtlanta$749
- Ajibola BabatundeAcworth$549
- Patrice MarshallDecatur$453
- Stacy SeikelDahlonega$414
- Claire TuckerStatesboro$352
- Sabrina HannaDahlonega$271
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.